Myhibbin in Egypt
How patients in Egypt access Myhibbin (nintedanib class) via Named Patient Program.
Myhibbin - overview
Myhibbin (nintedanib class) is manufactured by Boehringer Ingelheim (verify) and indicated for prophylaxis of organ rejection in adult and pediatric recipients of allogeneic kidney, heart, or liver transplants. It is an oral suspension, ready-to-use (no reconstitution) approved by the US FDA in 2024 and may be accessible to patients in Egypt through a Named Patient Program or personal-import pathway.
Access in Egypt
Egypt's EDA permits personal-use import of non-registered drugs under physician supervision; process is paperwork-heavy but viable.
How Reserve Meds coordinates access in Egypt
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Egypt-specific eligibility.
- Treating physician in Egypt issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Myhibbin from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Egypt.
Typical timeline for Egypt
End-to-end, most requests are completed in 2-6 weeks. Egypt's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Egypt ask
- Is the pathway legal in Egypt? Yes - it operates under Egypt's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Egypt able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.